| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727794-26-000004.txt","as_of":"2026-04-03T11:12:58.166696+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727794-26-000004.txt","company":"VYNE Therapeutics Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727794-26-000004.txt","article_chars":1881,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_751ee696943139a6","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727794-26-000004.txt","content_type":"text/plain","enriched_at":"2026-04-03T12:42:44.852032+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727794-26-000004.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727794-26-000004.txt","source_event_id":"evt_f196d895c6f7","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"605bd65ff2289c2d","kind":"sec_filing","published_at":"20260402","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-02","2026-03-31"],"entities":[{"asset_class":"equity","name":"VYNE Therapeutics Inc.","relevance":"high","symbol":"VYNE","type":"company"}],"event_type":"listing","information_gaps":["No specific financial implications or guidance provided in the filing."],"key_facts":["Form 4 filed on April 2, 2026.","Reporting owner: David Domzalski, President and CEO.","Change date: March 31, 2026.","Shares withheld for tax purposes: 14,232."],"numeric_claims":[{"label":"Shares withheld for tax purposes","value":"14,232"}],"primary_claim":"David Domzalski, President and CEO of VYNE Therapeutics Inc., reported changes in ownership of common stock due to tax withholding requirements.","relevance_score":0.7,"sentiment":"neutral","source_quality":"medium","summary":"VYNE Therapeutics Inc. filed a Form 4 on April 2, 2026, disclosing changes related to the ownership of common stock by David Domzalski, the President and CEO.","topics":["SEC Filing","Insider Trading"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 VYNE Therapeutics Inc. \u00b7 Filed 20260402","ticker":"VYNE","tickers":["VYNE"],"title":"VYNE filed 4","url":"https://www.sec.gov/Archives/edgar/data/1566044/0001727794-26-000004.txt"}... |